Citius Pharmaceuticals discontinues Suprenza to focus on core assets

Citius CEO Myron Holubiak said, "Suprenza no longer meets our core strategic objectives. We are dedicating our focus on our Phase 3 asset Mino-Lok and our Phase 2b asset Hydro-Lido for hemorrhoids.

"We feel that the obesity and weight management market has shifted and therefore we are devoting our efforts on developing our leading two assets.

"We anticipate a minimal financial impact to Citius from discontinuation since we eliminate our ongoing regulatory expenses and have not historically received royalties from the product."

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients.